VIEMED HEALTHCARE ANNOUNCES RESPONSE TO COVID-19 VIRUS
March 17 2020 - 8:52AM
Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX: VMD.TO
and NASDAQ:VMD), a home medical equipment supplier that provides
post-acute respiratory care services in the United States,
announced today its response to the growing number of COVID-19
cases around the country.
As a leader in the homecare ventilation market,
the Company began modifying its protocols last week in order to
ensure the safety of all of its employees as well as the safety of
all of its patients that are being serviced around the country. The
Company is currently delaying all non-essential home visits to
protect its high risk patients. The Company’s existing policies and
procedures will apply to setting up new patients as well as to any
emergency calls that require a home visit.
The Company is closely monitoring any
instructions and guidance issued by the Centers for Disease Control
and Prevention (CDC) in order to best protect its employees and
patients. The Company is also working with local officials
nationwide in the areas that it services so that potential needs
may be addressed by the Company’s network of clinicians.
“We have modified our procedures to immediately
focus on the health and safety of our employees and existing
patient base,” said Casey Hoyt, Viemed CEO. “With one of the
country's largest networks of respiratory therapists, we remain in
position to safely treat the growing patient base with our
significant ventilator fleet and our remote patient monitoring
capabilities. We stand ready to work with the CDC, state and local
agencies, and other hospital systems to treat the expected growing
number of COVID-19 patients in the home. Viemed's solution of
treating patients in their homes will potentially free up more
hospital beds for the growing patient base resulting from the
COVID-19 pandemic.”
ABOUT VIEMED HEALTHCARE, INC.
Viemed, through its indirect wholly-owned
subsidiaries Sleep Management, L.L.C. and Home Sleep Delivered,
L.L.C., is a home medical equipment supplier that provides
post-acute respiratory care services in the United States. Sleep
Management, L.L.C. focuses on disease management and improving the
quality of life for respiratory patients through clinical
excellence, education, and technology. Its service offerings are
based on effective home treatment with respiratory care
practitioners providing therapy and counseling to patients in their
homes using cutting edge technology. Home Sleep Delivered, L.L.C.
focuses on providing in-home sleep testing for sleep apnea
sufferers. Visit our website at www.viemed.com.
For further information, please contact:
Glen AkselrodBristol
Capital905-326-1888glen@bristolir.com
Todd ZehnderChief Operating OfficerViemed Healthcare,
Inc.337-504-3802investorinfo@viemed.com
Forward-Looking Statements
Certain statements contained in this press
release may constitute “forward-looking statements” within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 or “forward-looking information” as such term is defined in
applicable Canadian securities legislation (collectively,
“forward-looking statements”). Often, but not always,
forward-looking statements can be identified by the use of words
such as “plans”, “expects”, “is expected”, “budget”, “potential”,
“scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or
“believes”, “projects”, or the negatives thereof or variations of
such words and phrases or statements that certain actions, events
or results “will”, “should”, “may”, “could”, “would”, “might” or
“will be taken”, “occur” or “be achieved” or the negative of these
terms or comparable terminology. All statements other than
statements of historical fact, including those that express, or
involve discussions as to, expectations, beliefs, plans,
objectives, assumptions or future events or performance, including
the Company's response to the COVID-19 virus, are not historical
facts and may be forward-looking statements and may involve
estimates, assumptions and uncertainties that could cause actual
results or outcomes to differ materially from those expressed in
the forward-looking statements. Such statements reflect the
Company's current views and intentions with respect to future
events, and current information available to the Company, and are
subject to certain risks, uncertainties and assumptions. Many
factors could cause the actual results, performance or achievements
that may be expressed or implied by such forward-looking statements
to vary from those described herein should one or more of these
risks or uncertainties materialize. These factors include, without
limitation: the general business, market and economic conditions in
the regions in which the Company operates; the Company may be
subject to significant capital requirements and operating risks;
the ability of the Company to implement business strategies and
pursue business opportunities; volatility in the market price of
shares in the capital of the Company; the Company’s novel business
model; the risk that the clinical application of treatments that
demonstrate positive results in a study may not be positively
replicated or that such test results may not be predictive of
actual treatment results or may not result in the adoption of such
treatments by providers; the state of the capital markets; the
availability of funds and resources to pursue operations; decline
of reimbursement rates; dependence on few payors; possible new drug
discoveries; dependence on key suppliers; granting of permits and
licenses in a highly regulated business; competition; low profit
market segments; disruptions in or attacks (including
cyber-attacks) on the Company's information technology, internet,
network access or other voice or data communications systems or
services; the evolution of various types of fraud or other criminal
behavior to which the Company is exposed; the failure of third
parties to comply with their obligations; difficulty integrating
newly acquired businesses; the impact of new and changes to, or
application of, current laws and regulations; the overall difficult
litigation and regulatory environment; increased competition;
changes in foreign currency rates; increased funding costs and
market volatility due to market illiquidity and competition for
funding; critical accounting estimates and changes to accounting
standards, policies, and methods used by the Company; the impact of
the previously disclosed restatement and correction of our
previously issued financial statements; the previously disclosed
identified material weakness in our internal control over financial
reporting and our ability to remediate that material weakness; the
initiation of legal or regulatory proceedings with respect to the
restatement and corrections; the adverse effects on our business,
results of operations, financial condition and stock price, as a
result of the restatement and correction process; the Company’s
status as an emerging growth company and a foreign private issuer;
and the occurrence of natural and unnatural catastrophic events or
health epidemics or concerns, such as the recent COVID-19 outbreak,
and claims resulting from such events or concerns; as well as those
risk factors discussed or referred to in the Company’s disclosure
documents filed with the U.S. Securities and Exchange Commission
(the “SEC”) available on the SEC’s website at www.sec.gov,
including the Company’s most recent Annual Report on Form 10-K, and
with the securities regulatory authorities in certain provinces of
Canada available at www.sedar.com. Should any factor affect the
Company in an unexpected manner, or should assumptions underlying
the forward-looking statements prove incorrect, the actual results
or events may differ materially from the results or events
predicted. Any such forward-looking statements are expressly
qualified in their entirety by this cautionary statement. Moreover,
the Company does not assume responsibility for the accuracy or
completeness of such forward-looking statements. The
forward-looking statements included in this press release are made
as of the date of this press release and the Company undertakes no
obligation to publicly update or revise any forward-looking
statements, other than as required by applicable law.
Viemed Healthcare (TSX:VMD)
Historical Stock Chart
From Apr 2024 to May 2024
Viemed Healthcare (TSX:VMD)
Historical Stock Chart
From May 2023 to May 2024